Hormonal therapies in acne (Q34706886)

4 August 2017

1 reference

title

Hormonal therapies in acne (English)

1 reference

4 August 2017

James C Shaw

1

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

Expert Opinion on Pharmacotherapy

4 August 2017

published in

1 reference

4 August 2017

volume

3

1 reference

4 August 2017

issue

7

1 reference

4 August 2017

page(s)

865-874

1 reference

Predictors of severity of acne vulgaris in young adolescent girls: results of a five-year longitudinal study.

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.865

Hyperandrogenemia in patients presenting with acne

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.865

The role of androgens in determining acne severity in adult women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.865

Sebocytes are the key regulators of androgen homeostasis in human skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.865

Immunolocalization of 5alpha-reductase isozymes in acne lesions and normal skin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.865

A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.865

Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.865

Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.865

Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.865

Desogestrel, norgestimate, and gestodene: the newer progestins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.865

Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.865

Net effect of oral contraceptive use on the risk of cancer in women in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.865

Drospirenone: pharmacology and pharmacokinetics of a unique progestogen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.865

Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.865

Oral spironolactone improves acne vulgaris and reduces sebum excretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.865

Tolerance of spironolactone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.865

Spironolactone-induced hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.865

Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.865

Acute hepatitis induced by cyproterone acetate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.865

Cyproterone acetate: a genotoxic carcinogen?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.865

New topical antiandrogenic formulations can stimulate hair growth in human bald scalp grafted onto mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.865

Clinical breast and pelvic examination requirements for hormonal contraception: Current practice vs evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.7.865

21 January 2018

Identifiers

DOI

10.1517/14656566.3.7.865

1 reference

4 August 2017

1 reference